HCK proto-oncogene, Src family tyrosine kinase | Src family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

HCK proto-oncogene, Src family tyrosine kinase

  Target has curated data in GtoImmuPdb

Target id: 2032

Nomenclature: HCK proto-oncogene, Src family tyrosine kinase

Abbreviated Name: Hck

Family: Src family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 526 20q11-q12 HCK HCK proto-oncogene, Src family tyrosine kinase
Mouse - 524 2 H1 Hck hemopoietic cell kinase
Rat - 524 3 q41 Hck HCK proto-oncogene, Src family tyrosine kinase
Previous and Unofficial Names
Bmk | JTK9 | p56Hck | hemopoietic cell kinase | HCK proto-oncogene
Database Links
BRENDA
CATH/Gene3D
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY-SELECTIVE TYROSINE KINASE INHIBITOR
PDB Id:  1QCF
Resolution:  2.0Å
Species:  Human
References:  12
Image of receptor 3D structure from RCSB PDB
Description:  SRC FAMILY KINASE HCK SH3 DOMAIN
PDB Id:  1BU1
Resolution:  2.6Å
Species:  Human
References:  3
Enzyme Reaction
EC Number: 2.7.10.2

Download all structure-activity data for this target as a CSV file

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 2 [PMID: 15546730] Hs Inhibition 8.7 pIC50 7
pIC50 8.7 (IC50 2x10-9 M) [7]
eCF506 Hs Inhibition 8.6 pIC50 9
pIC50 8.6 (IC50 2.8x10-9 M) [9]
PP121 Hs Inhibition 8.1 pIC50 2
pIC50 8.1 (IC50 8x10-9 M) [2]
pexmetinib Hs Inhibition 7.6 pIC50 4
pIC50 7.6 (IC50 2.6x10-8 M) [4]
ibrutinib Hs Inhibition 7.5 pIC50 6
pIC50 7.5 (IC50 2.9x10-8 M) [6]
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 8,13

Key to terms and symbols Click column headers to sort
Target used in screen: HCK
Ligand Sp. Type Action Value Parameter
dasatinib Hs Inhibitor Inhibition 9.5 pKd
PD-173955 Hs Inhibitor Inhibition 8.5 pKd
bosutinib Hs Inhibitor Inhibition 8.5 pKd
foretinib Hs Inhibitor Inhibition 7.8 pKd
staurosporine Hs Inhibitor Inhibition 7.7 pKd
tamatinib Hs Inhibitor Inhibition 6.8 pKd
PP-242 Hs Inhibitor Inhibition 6.7 pKd
lestaurtinib Hs Inhibitor Inhibition 6.6 pKd
vandetanib Hs Inhibitor Inhibition 6.4 pKd
nilotinib Hs Inhibitor Inhibition 6.4 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx


Reference: 1,10

Key to terms and symbols Click column headers to sort
Target used in screen: Hck (activated)/nd
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
TWS119 Hs Inhibitor Inhibition -3.0 -1.0
K-252a Hs Inhibitor Inhibition 1.0 4.0
staurosporine Hs Inhibitor Inhibition 1.0 3.0
Lck inhibitor Hs Inhibitor Inhibition 1.0 -2.0
GSK-3 inhibitor IX Hs Inhibitor Inhibition 1.0 2.0
GSK-3 inhibitor X Hs Inhibitor Inhibition 3.0 -1.0
tivozanib Hs Inhibitor Inhibition 5.0 6.0
Flt-3 inhibitor II Hs Inhibitor Inhibition 8.0 3.0
indirubin derivative E804 Hs Inhibitor Inhibition 8.0 7.0
indirubin-3'-monoxime Hs Inhibitor Inhibition 8.0 1.0
Target used in screen: Hck/HCK
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
dasatinib Hs Inhibitor Inhibition 0.8
Lck inhibitor Hs Inhibitor Inhibition 2.2 2.0 1.0
staurosporine Hs Inhibitor Inhibition 3.3 1.5 2.0
PDGF RTK inhibitor Hs Inhibitor Inhibition 4.9 7.0 1.0
TWS119 Hs Inhibitor Inhibition 6.7 4.0 1.0
bosutinib Hs Inhibitor Inhibition 11.9
K-252a Hs Inhibitor Inhibition 13.2 3.0 1.0
GSK-3 inhibitor IX Hs Inhibitor Inhibition 13.3 6.0 1.0
Src kinase inhibitor I Hs Inhibitor Inhibition 13.5 4.0 5.0
midostaurin Hs Inhibitor Inhibition 14.9 7.0 5.0
Displaying the top 10 most potent ligands  View all ligands in screen »
Immunopharmacology Comments
Hck is thought to be involved in neutrophil migration, potentially via binding to intergrins [5].
Cell Type Associations
Immuno Cell Type:  Granulocytes
Cell Ontology Term:   eosinophil (CL:0000771)
neutrophil (CL:0000775)
References:  11
Immuno Cell Type:  Dendritic cells
References:  11
Immuno Cell Type:  Macrophages & monocytes
Cell Ontology Term:   monocyte (CL:0000576)
macrophage (CL:0000235)
References:  11
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 7 GO processes
GO:0002522 leukocyte migration involved in immune response TAS
GO:0002758 innate immune response-activating signal transduction TAS
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis TAS
GO:0050727 regulation of inflammatory response TAS
GO:0050764 regulation of phagocytosis IMP
GO:0060333 interferon-gamma-mediated signaling pathway TAS
click arrow to show/hide IEA associations
GO:0006954 inflammatory response IEA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 3 GO processes
GO:0002758 innate immune response-activating signal transduction TAS
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis TAS
GO:0050727 regulation of inflammatory response TAS
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 2 GO processes
GO:0019221 cytokine-mediated signaling pathway TAS
GO:0060333 interferon-gamma-mediated signaling pathway TAS
Immuno Process:  Chemotaxis & migration
GO Annotations:  Associated to 1 GO processes
GO:0002522 leukocyte migration involved in immune response TAS
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 2 GO processes
GO:0002758 innate immune response-activating signal transduction TAS
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis TAS

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol., 4 (11): 691-9. [PMID:18849971]

3. Arold S, O'Brien R, Franken P, Strub MP, Hoh F, Dumas C, Ladbury JE. (1998) RT loop flexibility enhances the specificity of Src family SH3 domains for HIV-1 Nef. Biochemistry, 37 (42): 14683-91. [PMID:9778343]

4. Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S et al.. (2016) Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer Res., 76 (16): 4841-4849. [PMID:27287719]

5. Baruzzi A, Iacobucci I, Soverini S, Lowell CA, Martinelli G, Berton G. (2010) c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration. FEBS Lett., 584 (1): 15-21. [PMID:19903482]

6. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al.. (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med., 374 (4): 323-32. [PMID:26641137]

7. Chen P, Norris D, Das J, Spergel SH, Wityak J, Leith L, Zhao R, Chen BC, Pitt S, Pang S et al.. (2004) Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg. Med. Chem. Lett., 14 (24): 6061-6. [PMID:15546730]

8. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

9. Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, Muir M, Harrington L, Webster SP, Frame MC et al.. (2016) Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. J. Med. Chem., 59 (10): 4697-710. [PMID:27115835]

10. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

11. Lowell CA. (2004) Src-family kinases: rheostats of immune cell signaling. Mol. Immunol., 41 (6-7): 631-43. [PMID:15220000]

12. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. (1999) Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell, 3 (5): 639-48. [PMID:10360180]

13. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

How to cite this page

Src family: HCK proto-oncogene, Src family tyrosine kinase. Last modified on 24/04/2018. Accessed on 17/10/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2032.